2026-07-21T14:57:56Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/184752024-11-28T14:48:39Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Gómez-Perez, Ana María author Damas-Fuentes, Miguel author Cornejo-Pareja, Isabel author Tinahones, Francisco J. author 2021-09-29 Heart failure (HF) has been a hot topic in diabetology in the last few years, mainly due to the central role of sodium-glucose cotransporter 2 inhibitors (iSGLT2) in the prevention and treatment of cardiovascular disease and heart failure. It is well known that HF is a common complication in diabetes. However, most of the knowledge about it and the evidence of cardiovascular safety trials with antidiabetic drugs refer to type 2 diabetes (T2D). The epidemiology, etiology, and pathophysiology of HF in type 1 diabetes (T1D) is still not well studied, though there are emerging data about it since life expectancy for T1D has increased in the last decades and there are more elderly patients with T1D. The association of T1D and HF confers a worse prognosis than in T2D, thus it is important to investigate the characteristics, risk factors, and pathophysiology of this disease in order to effectively design prevention strategies and therapeutic tools. 10.3390/jcm10194497 2077-0383 Journal of Clinical Medicine http://hdl.handle.net/10668/4458 34640518 http://hdl.handle.net/20.500.12105/18475 Type 1 diabetes Heart failure Cardiovascular disease Diabetic myocardiopathy Diabetes Mellitus tipo 1 Insuficiencia cardíaca Enfermedades cardiovasculares Cardiomiopatías Complicaciones de la diabetes Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review